These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25117499)

  • 1. Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery.
    Patel D; Bauman JD; Arnold E
    Prog Biophys Mol Biol; 2014; 116(2-3):92-100. PubMed ID: 25117499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin.
    Wollenhaupt J; Barthel T; Lima GMA; Metz A; Wallacher D; Jagudin E; Huschmann FU; Hauß T; Feiler CG; Gerlach M; Hellmig M; Förster R; Steffien M; Heine A; Klebe G; Mueller U; Weiss MS
    J Vis Exp; 2021 Mar; (169):. PubMed ID: 33749678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fast fragment and compound screening pipeline at the Swiss Light Source.
    Stegmann DP; Steuber J; Fritz G; Wojdyla JA; Sharpe ME
    Methods Enzymol; 2023; 690():235-284. PubMed ID: 37858531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystallographic fragment screening in academic cancer drug discovery.
    Martin MP; Endicott JA; Noble MEM; Tatum NJ
    Methods Enzymol; 2023; 690():211-234. PubMed ID: 37858530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystallographic fragment screening.
    Badger J
    Methods Mol Biol; 2012; 841():161-77. PubMed ID: 22222452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fast fragment- and compound-screening pipeline at the Swiss Light Source.
    Kaminski JW; Vera L; Stegmann DP; Vering J; Eris D; Smith KML; Huang CY; Meier N; Steuber J; Wang M; Fritz G; Wojdyla JA; Sharpe ME
    Acta Crystallogr D Struct Biol; 2022 Mar; 78(Pt 3):328-336. PubMed ID: 35234147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the success of fragment screening by X-ray crystallography.
    Davies DR; Begley DW; Hartley RC; Staker BL; Stewart LJ
    Methods Enzymol; 2011; 493():91-114. PubMed ID: 21371588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The genesis of high-throughput structure-based drug discovery using protein crystallography.
    Kuhn P; Wilson K; Patch MG; Stevens RC
    Curr Opin Chem Biol; 2002 Oct; 6(5):704-10. PubMed ID: 12413557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving a Good Crystal System for Crystallographic X-Ray Fragment Screening.
    Collins PM; Douangamath A; Talon R; Dias A; Brandao-Neto J; Krojer T; von Delft F
    Methods Enzymol; 2018; 610():251-264. PubMed ID: 30390801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-plate protein crystallization, in situ ligand soaking and X-ray diffraction.
    le Maire A; Gelin M; Pochet S; Hoh F; Pirocchi M; Guichou JF; Ferrer JL; Labesse G
    Acta Crystallogr D Biol Crystallogr; 2011 Sep; 67(Pt 9):747-55. PubMed ID: 21904027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening Ligands by X-ray crystallography.
    Davies DR
    Methods Mol Biol; 2014; 1140():315-23. PubMed ID: 24590727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-based activity space: smaller is better.
    Hesterkamp T; Whittaker M
    Curr Opin Chem Biol; 2008 Jun; 12(3):260-8. PubMed ID: 18316043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment screening: an introduction.
    Leach AR; Hann MM; Burrows JN; Griffen EJ
    Mol Biosyst; 2006 Sep; 2(9):430-46. PubMed ID: 17153140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fragment-based screening by X-ray structure analysis].
    Yamano A
    Yakugaku Zasshi; 2010 Mar; 130(3):335-40. PubMed ID: 20190518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-based screening by protein crystallography: successes and pitfalls.
    Chilingaryan Z; Yin Z; Oakley AJ
    Int J Mol Sci; 2012 Oct; 13(10):12857-79. PubMed ID: 23202926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment-based screening using X-ray crystallography and NMR spectroscopy.
    Jhoti H; Cleasby A; Verdonk M; Williams G
    Curr Opin Chem Biol; 2007 Oct; 11(5):485-93. PubMed ID: 17851109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-guided fragment screening for lead discovery.
    Verdonk ML; Hartshorn MJ
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):404-10. PubMed ID: 15338949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein X-ray Crystallography and Drug Discovery.
    Maveyraud L; Mourey L
    Molecules; 2020 Feb; 25(5):. PubMed ID: 32106588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining 'dry' co-crystallization and in situ diffraction to facilitate ligand screening by X-ray crystallography.
    Gelin M; Delfosse V; Allemand F; Hoh F; Sallaz-Damaz Y; Pirocchi M; Bourguet W; Ferrer JL; Labesse G; Guichou JF
    Acta Crystallogr D Biol Crystallogr; 2015 Aug; 71(Pt 8):1777-87. PubMed ID: 26249358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and optimization of PDE10A inhibitors using fragment-based screening by nanocalorimetry and X-ray crystallography.
    Recht MI; Sridhar V; Badger J; Bounaud PY; Logan C; Chie-Leon B; Nienaber V; Torres FE
    J Biomol Screen; 2014 Apr; 19(4):497-507. PubMed ID: 24375910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.